| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
8-Hydroxyadenosine does not have a defined biological target as it is a marker of oxidative stress. It is an oxidized nucleoside that can be incorporated into RNA and DNA, potentially affecting nucleic acid function and stability. It is a purine nucleoside oxidation product that serves as a biomarker of oxidative stress and cellular damage. The compound is used to study the role of oxidative damage in various diseases, including cancer and neurodegenerative disorders.
|
|---|---|
| ln Vitro |
In vitro, 8-hydroxyadenosine is used as a reference or reagent in studies of nucleic acid oxidation, RNA modification, and assays of oxidative stress. It is a purine nucleoside that has been used to study the binding and activation of ribonuclease L by 2',5'-oligoadenylates. The compound is an oxidized nucleic acid adduct and a precursor of phosmidosine (a P-prodrug). It is commonly used as a biomarker of oxidative stress.
|
| ln Vivo |
8-Hydroxyadenosine is not a pharmacologically active drug and does not exhibit in vivo therapeutic activity. It is a biomarker of oxidative stress and cellular damage. The compound is used in research to understand the role of oxidative damage in various diseases, including cancer and neurodegenerative disorders. It is not intended for therapeutic use.
|
| Enzyme Assay |
In vitro assays for 8-hydroxyadenosine typically involve nucleic acid oxidation and RNA modification studies. A standard protocol involves preparing a solution of the compound in an appropriate solvent (e.g., water or buffer) and using it as a standard or reagent for LC-MS analysis of oxidized nucleosides in biological samples. The compound is used as a reference for the identification and quantification of 8-hydroxyadenosine in nucleic acid oxidation studies.
|
| Cell Assay |
In vitro cell culture experiments with 8-hydroxyadenosine are not standard, as it is primarily an analytical standard and biomarker. When studying oxidative stress, cells are treated with oxidizing agents, and 8-hydroxyadenosine levels are measured by LC-MS. The compound is not used as a test compound for biological activity but as a marker of oxidative damage.
|
| Animal Protocol |
In vivo animal studies are not conducted with 8-hydroxyadenosine, as it is a biomarker and analytical standard. The compound is used to measure oxidative stress in animal models of disease. Levels of 8-hydroxyadenosine in tissues or biological fluids are measured by LC-MS to assess oxidative damage.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 8-hydroxyadenosine are not characterized, as it is not a drug substance. The compound is a naturally occurring oxidized nucleoside that is generated as a byproduct of oxidative stress. It is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
8-Hydroxyadenosine is a research reagent and should be handled with standard laboratory precautions, including the use of gloves and safety glasses. The compound should be stored in a cool, dry place away from light and moisture. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| References |
[1]. Kanou M, et al. Purine 8-substitution modulates the ribonuclease L binding and activation abilities of 2',5'-oligoadenylates. Biochem Biophys Res Commun. 1991 Apr 30;176(2):769-74.
|
| Additional Infomation |
8-Hydroxyadenosine is a purine nucleoside oxidation product of adenosine. It is often generated as a byproduct of oxidative stress and is considered a marker of cellular damage. 8-Hydroxyadenosine is used as a reference or reagent in studies of nucleic acid oxidation, RNA modification, and assays of oxidative stress. It has not undergone clinical trials and is not approved as a pharmaceutical.
|
| Molecular Formula |
C10H13N5O5
|
|---|---|
| Molecular Weight |
283.24
|
| Exact Mass |
285.107
|
| CAS # |
29851-57-8
|
| PubChem CID |
96852
|
| Appearance |
White to off-white solid powder
|
| Density |
1.806g/cm3
|
| Boiling Point |
776.3ºC at 760 mmHg
|
| Flash Point |
423.3ºC
|
| Vapour Pressure |
2.29E-25mmHg at 25°C
|
| Index of Refraction |
1.754
|
| LogP |
-2.5
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
398
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
OC[C@@H]1[C@H]([C@H]([C@H](N2C(NC3=C(NCN=C32)N)=O)O1)O)O
|
| InChi Key |
UEHOMUNTZPIBIL-UUOKFMHZSA-N
|
| InChi Code |
InChI=1S/C10H13N5O5/c11-7-4-8(13-2-12-7)15(10(19)14-4)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H,14,19)(H2,11,12,13)/t3-,5-,6-,9-/m1/s1
|
| Chemical Name |
6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-purin-8-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5306 mL | 17.6529 mL | 35.3057 mL | |
| 5 mM | 0.7061 mL | 3.5306 mL | 7.0611 mL | |
| 10 mM | 0.3531 mL | 1.7653 mL | 3.5306 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
